Skip to main content
. 2023 Mar 9;98(5):770–783. doi: 10.1002/ajh.26889

FIGURE 4.

FIGURE 4

Effects of JAK2 inhibitors on expression of target antigens in MPN NSC. Primary MNC from JAK2V617F+ MPN patients were incubated in control medium (Co) or medium containing fedratinib (1–5 μM) or ruxolitinib (1–10 μM) at 37°C for 24 h. Expression of selected cell surface antigens (up‐ or down‐regulated on MPN stem cells) on CD34+/CD38− stem cells were evaluated by multicolor flow cytometry and shown as staining index (% of control). Results represent the mean ± SD from up to six JAK2V617F+ MPN patients. Significance levels of differences in expression of surface antigens between the different conditions were analyzed by one‐way analysis of variance (ANOVA) with Dunnett's post hoc test (*p < .05 compared to control). EPOR, erythropoietin receptor; MNC, mononuclear cells; MPN, myeloproliferative neoplasm; NSC, neoplastic stem cells.